de la Torre BG, Albericio F. The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules. Vol. 29, Molecules. Multidisciplinary Digital Publishing Institute (MDPI); 2024.

Hamuro L, Kijanka G, Kinderman F, Kropshofer H, Bu D, xiu, Zepeda M, et al. Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins. Journal of Pharmaceutical Sciences. Volume 106. Elsevier B.V.; 2017. pp. 2946–54.

Turner MR, Balu-Iyer SV. Challenges and opportunities for the subcutaneous delivery of therapeutic proteins. Journal of Pharmaceutical Sciences. Volume 107. Elsevier B.V.; 2018. pp. 1247–60.

Viola M, Sequeira J, Seiça R, Veiga F, Serra J, Santos AC, et al. Subcutaneous delivery of monoclonal antibodies: how do we get there? J Controlled Release. 2018;286:301–14.

Article  CAS  Google Scholar 

Xu Z, Leu JH, Xu Y, Nnane I, Liva SG, Wang-Lin SX, et al. Development of therapeutic proteins for a new subcutaneous route of administration after the establishment of intravenous dosages: A systematic review. Clinical Pharmacology and Therapeutics. Volume 113. John Wiley and Sons Inc; 2023. pp. 1011–29.

Lyu X, Zhao Q, Hui J, Wang T, Lin M, Wang K, et al. The global landscape of approved antibody therapies. Antibody Therapeutics. Volume 5. Oxford University Press; 2022. pp. 233–57.

Pitiot A, Heuzé-Vourc’h N, Sécher T. Alternative routes of administration for therapeutic Antibodies—State of the Art. Volume 11. Antibodies. MDPI; 2022.

Marschall C, Witt M, Hauptmeier B, Frieß W. Drug product characterization of high concentration Non-Aqueous protein powder suspensions. J Pharm Sci. 2023;112(1):61–75.

Article  CAS  PubMed  Google Scholar 

Garidel P, Kuhn AB, Schäfer LV, Karow-Zwick AR, Blech M. High-concentration protein formulations: how high is high? Eur J Pharm Biopharm. 2017;119:353–60.

Article  CAS  PubMed  Google Scholar 

Lou H, Feng M, Hageman MJ. Advanced formulations/drug delivery systems for subcutaneous delivery of Protein-Based biotherapeutics. Journal of Pharmaceutical Sciences. Volume 111. Elsevier B.V.; 2022. pp. 2968–82.

Zarzar J, Khan T, Bhagawati M, Weiche B, Sydow-Andersen J, Alavattam S. High concentration formulation developability approaches and considerations. Volume 15. mAbs. Taylor and Francis Ltd.; 2023.

Saluja A, Kalonia DS. Nature and consequences of protein–protein interactions in high protein concentration solutions. Int J Pharm. 2008;358(1–2):1–15.

Article  CAS  PubMed  Google Scholar 

Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci. 2004;93(6):1390–402.

Article  CAS  PubMed  Google Scholar 

Desai M, Kundu A, Hageman M, Lou H, Boisvert D. Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume. Volume 15. mAbs. Taylor and Francis Ltd.; 2023.

Whitaker N, Xiong J, Pace SE, Kumar V, Middaugh CR, Joshi SB, et al. A formulation development approach to identify and select stable Ultra–High-Concentration monoclonal antibody formulations with reduced viscosities. J Pharm Sci. 2017;106(11):3230–41.

Article  CAS  PubMed  Google Scholar 

Tomar DS, Kumar S, Singh SK, Goswami S, Li L. Molecular basis of high viscosity in concentrated antibody solutions: strategies for high concentration drug product development. Volume 8. mAbs. Taylor and Francis Inc.; 2016. pp. 216–28.

Hong T, Iwashita K, Shiraki K. Viscosity control of protein solution by small solutes: A review. Curr Protein Pept Sci. 2017;19(8):746–58.

Article  Google Scholar 

Dear BJ, Hung JJ, Laber JR, Wilks LR, Sharma A, Truskett TM, et al. Enhancing stability and reducing viscosity of a monoclonal antibody with cosolutes by weakening Protein-Protein interactions. J Pharm Sci. 2019;108(8):2517–26.

Article  CAS  PubMed  Google Scholar 

Svilenov HL, Kulakova A, Zalar M, Golovanov AP, Harris P, Winter G. Orthogonal techniques to study the effect of pH, sucrose, and arginine salts on monoclonal antibody physical stability and aggregation during Long-Term storage. J Pharm Sci. 2020;109(1):584–94.

Article  CAS  PubMed  Google Scholar 

Sahin E, Deshmukh S. Challenges and considerations in development and manufacturing of high concentration biologics drug products. Journal of Pharmaceutical Innovation. Volume 15. Springer; 2020. pp. 255–67.

Piedmonte DM, Gu JH, Brych SR, Goss MM. In. Practical considerations for high concentration protein formulations. AAPS Advances in the Pharmaceutical Sciences Series, vol 38. Springer, Cham.2018. pp. 163–87.

Locke KW, Maneval DC, LaBarre MJ. ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Delivery. Volume 26. Taylor and Francis Ltd; 2019. pp. 98–106.

Nolan RP, Printz MA. Modeling the subcutaneous pharmacokinetics of antibodies co-administered with rHuPH20. Clin Transl Sci. 2024;17(4).

Halozyme. ENHANZE [Internet]. [cited 2024 Sep 20]. Available from: https://halozyme.com/drug-delivery-technologies/enhanze/

Srinivasan C, Weight AK, Bussemer T, Klibanov AM. Non-aqueous suspensions of antibodies are much less viscous than equally concentrated aqueous solutions. Pharm Res. 2013;30(7):1749–57.

Article  CAS  PubMed  Google Scholar 

Marschall C, Witt M, Hauptmeier B, Friess W. Powder suspensions in non-aqueous vehicles for delivery of therapeutic proteins. Eur J Pharm Biopharm. 2021;161:37–49.

Article  CAS  PubMed  Google Scholar 

Yang MX, Shenoy B, Disttler M, Patel R, McGrath M, Pechenov S et al. Crystalline monoclonal antibodies for subcutaneous delivery. Proceedings of the National Academy of Sciences. 2003;100(12):6934–9.

Bowen M, Armstrong N, Maa Yfun. Investigating High-Concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection. J Pharm Sci. 2012;101(12):4433–43.

Article  CAS  PubMed  Google Scholar 

Shire SJ, Liu J, Friess W, Jörg S, Mahler HC. In: Jameel F, Hershenson S, editors. High-concentration antibody formulations. Hoboken: John Wiley & Sons, Inc; 2010. pp. 357–8.

Google Scholar 

Basu SK, Govardhan CP, Jung CW, Margolin AL. Protein crystals for the delivery of biopharmaceuticals. Expert Opin Biol Ther. 2004;4(3):301–17.

Article  CAS  PubMed  Google Scholar 

Erfani A, Schieferstein JM, Reichert P, Narasimhan CN, Pastuskovas C, Parab V et al. Crystalline Antibody-Laden alginate particles: A platform for enabling high concentration subcutaneous delivery of antibodies. Adv Healthc Mater. 2023;12(15).

Miller MA, Engstrom JD, Ludher BS, Johnston KP. Low viscosity highly concentrated injectable nonaqueous suspensions of lysozyme microparticles. Langmuir. 2010;26(2):1067–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Angkawinitwong U, Sharma G, Khaw PT, Brocchini S, Williams GR. Solid-state protein formulations. Ther Deliv. 2015;6(1):59–82.

Article  CAS  PubMed  Google Scholar 

Chang LL, Pikal MJ. Mechanisms of protein stabilization in the solid state. Journal of Pharmaceutical Sciences. Volume 98. John Wiley and Sons Inc.; 2009. pp. 2886–908.

Chandrababu KB, Kannan A, Savage JR, Stadmiller S, Ryle AE, Cheung C et al. Stability comparison between Microglassification and lyophilization using a monoclonal antibody. J Pharm Sci [Internet]. 2023; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022354923004306

Badkar AV, Gandhi RB, Davis SP, Labarre MJ. Subcutaneous delivery of high-dose/volume biologics: current status and prospect for future advancements. Drug Design, Development and Therapy. Volume 15. Dove Medical Press Ltd; 2021. pp. 159–70.

Page S, Khan T, Kühl P, Schwach G, Storch K, Chokshi H. Patient Centricity Driving Formulation Innovation: Improvements in Patient Care Facilitated by Novel Therapeutics and Drug Delivery Technologies. 2024;34:51. Available from: https://doi.org/10.1146/annurev-pharmtox-052120-

Collins DS, Sánchez-Félix M, Badkar AV, Mrsny R. Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics. Journal of Controlled Release. Volume 321. Elsevier B.V.; 2020. pp. 475–82.

Jons CK, Prossnitz AN, Eckman N, Dong C, Appel EA. Glassy Surfactants Enable Ultra-High Concentration Biologic Therapeutics. Available from: https://doi.org/10.1101/2024.09.09.612104

FDA CDER. Immunogenicity Testing of Therapeutic Protein Products —Developing and Validating Assays for Anti-Drug Antibody Detection Guidance for Industry [Internet]. 2019. Available from: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm and/or https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm

Laurén A, Goodman J, Blaes J, Cook J, Cowan KJ, Dahlbäck M, et al. A strategic approach to nonclinical immunogenicity assessment: A recommendation from the European bioanalysis forum. Bioanalysis. 2021;13(7):537–49.

Article  PubMed  Google Scholar 

Anton Paar. The influence of particles on suspension rheology [Internet]. [cited 2025 Mar 10]. Available from: https://wiki.anton-paar.com/us-en/the-influence-of-particles-on-suspension-rheology/#:~:text=Particle%20fraction%2C%20shape%2C%20size%20(,fractions%20at%20high%20shear%20rates.).

Luckham PF, Ukeje MA. Effect of Particle Size Distribution on the Rheology of Dispersed Systems [Internet]. 1999. Available from: http://www.idealibrary.com

FDA. Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products Guidance for Industry DRAFT GUIDANCE. 2020; Available from: https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances

FDA. Bacterial Endotoxins/Pyrogens [Internet]. 2014 [cited 2025 March 11]. Available from: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-technical-guides/bacterial-endotoxinspyrogens

McDonald TA, Zepeda ML, Tomlinson MJ, Bee WH, Ivens IA. Subcutaneous administration of biotherapeutics: current experience in animal models. Curr Opin Mol Ther. 2010;12(4):461–70.

CAS  PubMed  Google Scholar 

Bitterfield D. Microglassification TM suspension of biologics for SC delivery of high concentration formulations. The biologics summit. Control Release Society. LasVegas; 2023.

Fitch R, Bowman D, Donovan M, Prestrelski S. Abstract LB024: pharmacokinetics of a novel viscoelastic suspension of trastuzumab biosimilar for high-concentration, low-volume subcutaneous injection. Cancer Res. 2023;83(8Supplement):LB024–024.

Article  Google Scholar 

Zurdo J, Arnell A, Obrezanova O, Smith N, de la Gómez R, Gallagher TRA, et al. Early implementation of QbD in biopharmaceutical development: A practical example. Biomed Res Int. 2015;2015:1–19.

Article  Google Scholar 

Wen Y, Jawa V. The impact of product and process related critical quality attributes on immunogenicity and adverse immunological effects of biotherapeutics. Journal of Pharmaceutical Sciences. Volume 110. Elsevier B.V.; 2021. pp. 1025–41.

Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The molecular mechanisms that underlie the immune biology of Anti-drug antibody formation following treatment with monoclonal antibodies. Frontiers in Immunology. Volume 11. Frontiers Media S.A.; 2020.

Ghosh I, Gutka H, Krause ME, Clemens R, Kashi RS. A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations. Volume 15. mAbs. Taylor and Francis Ltd.; 2023.

Deokar V, Sharma A, Mody R, Volety SM. Comparison of strategies in development and manufacturing of low viscosity, Ultra-High concentration formulation for IgG1 antibody. J Pharm Sci. 2020;109(12):3579–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woodley WD, Morel DR, Sutter DE, Pettis RJ, Bolick NG. Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults. Clin Transl Sci. 2022;15(1):92–104.

Article  CAS  PubMed  Google Scholar